XIAOYAN ZHANG MD, PhD

9/26/2014 XIAOYAN ZHANG MD, PhD PERSONAL INFORMATION 6550 Sanger Rd Office 475, Orlando, FL, 32827 E-mail: [email protected] Office: 407-313-7002 ...
Author: Todd Morton
33 downloads 3 Views 262KB Size
9/26/2014

XIAOYAN ZHANG MD, PhD PERSONAL INFORMATION 6550 Sanger Rd Office 475, Orlando, FL, 32827 E-mail: [email protected] Office: 407-313-7002

EDUCATION 2003-2008 Ph.D., Pharmacology and Toxicology, University of Louisville, KY 2000-2003 M.S., Epidemiology and Biostatistics, Fudan University, Shanghai, China 1995-2000 M.D., School of Public Health, Zhengzhou University, HeNan, China

EMPLOYMENT 2014-Present

Research Assistant Professor Center for Pharmacometrics & Systems Pharmacology Department of Pharmaceutics College of Pharmacy University of Florida, Orlando (Lake Nona), Florida

POST-GRADUATE EXPERIENCES Nov. 2011-2013

Icahn School of Medicine at Mount Sinai Dept. of Pharmacology and Systems Therapeutics, NY Post-doctoral Fellow (Advisor: Dr. James Gallo)

2008-Sep.2009

University at Buffalo, the State University of New York Dept. of Pharmaceutical Sciences, Buffalo, NY Research Scientist, Post-doctoral Fellow (Advisor: Dr. Joseph Balthasar)

PROFESSIONAL EXPERIENCES Jun 2006

Oxford University Dept. of Pharmacology, England Visiting Scholar

2005-2008

University of Louisville Dept. of Pharmacology and Toxicology, KY Research Assistant (Mentor Dr. David Hein)

2001-2002

Fudan University Dept. of Epidemiology, Shanghai, China Instructor and Research Assistant

2000

Department of Health Intern, Zhengzhou, Henan Province, China

1999

Zhengzhou University Affiliated Hospital Intern, Zhengzhou, China 1

RESEARCH PROJECTS  FAERS data mining including drug-drug interactions, drug risk factors and covariates identification in elucidating ADEs (e.g. APAP-SJS, and sunitinib-hypertension drugadverse events pairs)  Development of an enhanced PK/PD model for the VEGFR signaling pathway during the anti-cancer therapy for identification of novel drug targets and guidance of drug combination therapy  Characterization of Fcgmma and FcRn receptors in PK disposition and PD effect of monoclonal antibody in the immune thrombocytopenia (ITP) disease model  Pharmacogenomics characterization of NAT1 expression in breast cancer  Xenobiotic 4, 4’-methylenedianiline (MDA) hepatotoxicity modification by Nacetyltransferase 2 (NAT2) polymorphism in a preclinical rat model  Molecular and transcriptional characterization of NAT1/NAT2 promoter, transcription factors and gene expressions across tissues  An Epidemiology case-control study of liver cancer risk factors including both environment and genetic susceptibility

HONORS/AWARDS     

Graduate School Deans Citation Award (University of Louisville) GSC Travel Award (University of Louisville) Fellowship (University of Louisville) Excellent student - 1 of 2 Awardees (Fudan University) Outstanding thesis award (Zhengzhou University)

2005 & 2008 2006 2003-2005 2001 2000

PROFESSIONAL MEMBERSHIPS  Active member, American Association for Cancer Research (AACR)  American Society for Clinical Pharmacology and Therapeutics (ASCPT)

MEDICAL, HEALTH REGULATION AND TEACHING EXPERIENCES  Physician assistant: Departments of OBGYN, Cardiology, Respiratory, Emergency, Surgery and Oncology  Health regulation enforcement, health policy regulation and editing in training book  Teaching Courses: Epidemiology Study Design and Data Analysis to MD students and professional CDC employee students  Mentoring students in the Systems Biology Center New York program (SBCNY)  Mentoring various program students including MD, Ph.D., PharmD students as team effort to ensure the project success during the job responsibilities

JOURNAL REVIEW SERVICES  Pharmaceutical Research, Journal of Pharmacokinetics and Pharmacodynamics, Plos One, British Journal of Clinical Pharmacology, Journal of Pharmaceutical Sciences, Current Drug Metabolism et al.

ENROLLED TRAINING 2011 Systems Biology Center New York Symposium 1999-2003 Epidemiology; Multivariate Logistic Analysis; Biostatistics; SAS Application in 2

Medical Data Analysis; SPSS software Usage 2003-2005 Principles of Drug and Chemical Action; Biochemistry; Physiology; Cell Biology; Pharmacology, Cell Biology 2008-2010 NonMEM population PK/PD Modeling; Intermediate Pharmacokinetics (607) Advanced Pharmacokinetics (608); Advanced Pharmacodynamics (609); Workshop on Monolix (2 days); SimCYP (Intense 2 day course); Introduction to Antibody PK/PD; R Basic Training

EXPERTISES COMPUTATION  PK/PD Modeling and Simulation (mAb and Small Molecule) (WinNonlin, Matlab, NonMEM, SimCYP, R, Monolix)  Enhanced PK/PD Modeling and Simulation (Matlab)  Epidemiology Study Design, and Bio-statistical Analysis (EpiInfo, SAS,STATA, SPSS)  Large Database Construction and Data-Mining (SAS)

EXPERIMENTS Traditional Drug Research  In Vitro small molecule cytotoxicity Assay Preclinical Animal Experimental Testing  In Vivo handling and sample collection for PK/PD drug disposition, efficacy and toxicology study using preclinical mice and rat model  Histopathology and Immunohistochemistry Pharmacology & Molecular Biology  Drug Metabolizing Enzyme Pharmacogenomics  UCSC genome browser, GEO, ClustalW, Blat, Blast, IgBlast MatInspector, Transcription factor database, Mfold, Vector NTI design of plasmid construction  Cloning and transfection, Site-directed mutagenesis  Genotyping and Transcriptional Regulation of and gene expression  Monoclonal antibody production and purification  Enzyme kinetics, Western blot, ELISA, HPLC, Flow cytometry

POSTERS & PRESENTATIONS 1. Systems Approach: A-Proof-of-Concept Study to Improve Drug Safety. ACCP (Sep/2014) 2. A Computational Model and Sensitivity Analysis of the VEGFR-2 Signaling Pathway. SBCNY 2012 summer undergraduate Poster Session, New York City (Aug/2012) 3. Podium Presentation: PK/PD characterization of the role of Fcgamma receptor in the disposition and effect of antibody.1st CPT Symposium, Buffalo, NY (Jul/2009) 4. Investigation of the mechanism of increased N-acetyltransferase 1 (NAT1) expression in estrogen receptor positive breast cancer. Annual Meeting of SOT, Seattle, Washington (Mar/2008) 5. Effect of estrogen on NAT1 expression in breast tumor cells. 98th Annual Meeting of AACR, Los Angeles, California (Apr/2007) 6. Podium Presentation: Characterization of N-acetyltransferase 1(NAT1) over-expression in breast cancer. Immune Disease Institute, Harvard Medical School (Jun/2007)

3

7. Podium Presentation: Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements. FASEB Meeting (ASPET), Washington DC (May/2007) 8. Quantitation and characterization of N-acetyltransferase-2 mRNA in human tissues. FASEB Meeting (ASPET), Washington DC (May/2007) 9. Podium Presentation: NAT2 polymorphism modifies acute 4, 4’-methylenedianiline hepatotoxicity in the rat. Third International N-acetyltransferase Workshop, Vancouver, Canada (Aug/2004)

PUBLICATIONS 1. Xiaoyan Zhang, Mirjam N. Trame, Lawrence J. Lesko and Stephan Schmidt. (2014). Sobol Sensitivity Analysis: A tool to Guide the Development and Evaluation of Systems Pharmacology Models. CPT: Pharmacometrics & Systems Pharmacology (submitted.) 2. Xiaoyan Zhang, Marc R. Birtwistle, James M. Gallo (2014). A General Network Pharmacodynamic Model-Based Design Pipeline for Customized Cancer Therapy Applied to the VEGFR Pathway. Nature CPT: Pharmacometrics & Systems Pharmacology, 3:e92; doi:10.1038/psp.2013.65 3. Lubna Abuqayyas, Xiaoyan Zhang, Joseph P. Balthasar (2013). Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and antiplatelet effects of MWReg30, a monoclonal anti-GPIIb antibody. International Journal of Pharmaceutics, 444 (1-2):185-92. 4. Xiaoyan Zhang (2013). Genetic variation in prediction of drug efficacy and toxicity. Clinical Pharmacology Biopharmaceutics 2:e113. doi:10.4172/2167-065X.1000e113 5. Larissa Wakefield, Valerie Cornish, Hilary Long, Akane Kawamura, Xiaoyan Zhang, David W. Hein and Edith Sim (2008). Arylamine N-acetyltransferase 2 (Nat2) expression in the developing neuroendocrine system of the mouse. Biomarkers, 13(1): 106-118. 6. Anwar Husain, Xiaoyan Zhang, Mark A. Doll, J. Christopher States David F. Barker and David W. Hein (2007). Functional analysis of the human N-acetyltransferase 1 major promoter: Quantitation of tissue expression and identification of critical sequence elements. Drug Metabolism and Disposition. 35(9): 1649–1656. 7. Anwar Husain, Xiaoyan Zhang, Mark A. Doll, J.Christopher States, David F. Barker and David W. Hein (2007). Identification of N-Acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metabolism and Disposition. 35(5):721-7. 8. David F. Barker, Anwar Husain, Jason R.Neale, Benjamin D.Martini, Xiaoyan Zhang, Mark A.Doll, J.Christopher States and David W.Hein (2006). Functional properties of an alternatinve, tissue-specific promoter for the N-acetyltransferase-1 gene, NAT1. Pharmacogenet Genomics. 16(7): 515-525. 9. Xiaoyan Zhang, Jason C. Lambert, Mark A. Doll, Jason M. Walraven, Gavin E. Arteel and David W. Hein (2006). 4, 4’-methylenedianiline-induced hepatotoxicity is modified by Nacetyltransferase 2 (Nat2) acetylator polymorphism in the rat. Journal of Pharmacology and Experimental Therapeutics. 316(1): 289-294. 10. Xiufeng Zhang, Jianchao Bian, Xiaoyan Zhang, Zhumei Zhang, Feng Jiang, Qimin Wang, Qijun Wang, Yanyan Cao, Boming Tang (2005). Are polymorphisms of N-acetyltransferase genes susceptible to primary liver cancer in Luoyang, China? World J Gastroenterol. 11, 14571462. 11. Xiufeng Zhang, Xiaoyan Zhang, Jianchao Bian et al (2004). NAT1 genetic polymorphisms 4

and the susceptibility to hepatocellular carcinoma China Oncology. 14(3):207 (in Chinese) 12. Qijun Wang, Jianchao Bian, Zhumei Zhang, Qimin Wang, Xin Zhu, Weiwei Fan, Xiaoyan Zhang, Boming Tang (2003). Analysis of the association between alcohol intake and liver cancer in Luoyang. Journal of Practical Oncology. 18(1), 62-65. (in Chinese) 13. Boming Tang, Zhumei Zhang, Qijun Wang, Qimin Wang, Weiwei Fan, Xiaoyan Zhang, Jianchao Bian (2002). Case control study of association between alcohol intake and liver cancer. Journal of Practical Oncology. 16(2), 88-91. (in Chinese)

5

Suggest Documents